难治性免疫性血小板减少性紫癜长期临床病程中发生的多发性骨髓瘤：一例报告并文献复习
Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.
作者信息
Yao Han, Zhang Xi, Liu Jia, Zhu Lidan, Chen Guo, Wu Sha, Gao Lei
机构信息
Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
出版信息
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15429-32. eCollection 2015.
Abstract
Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease that is characterized by increased destruction of platelets by autoantibodies. Although the onset of the disease and clinical course are highly variable, the disease typically has a benign course. ITP associated with multiple myeloma (MM) has been rarely reported; it is even rarer for MM to develop during a long-term ITP (almost 20 years). Here, we first report on a case with a 20-year long clinical course of refractory ITP followed by newly diagnosed MM.
摘要
免疫性血小板减少症（ITP）是一种获得性免疫介导性疾病，其特征是自身抗体导致血小板破坏增加。尽管该疾病的起病和临床病程高度可变，但通常呈良性病程。与多发性骨髓瘤（MM）相关的ITP鲜有报道；MM在长期ITP（近20年）病程中发生则更为罕见。在此，我们首次报告一例难治性ITP长达20年临床病程后新发MM的病例。
相似文献
1
Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15429-32. eCollection 2015.
2
Immune thrombocytopenia purpura associated with multiple myeloma.
Ann Hematol. 2016 Aug;95(8):1371-2. doi: 10.1007/s00277-016-2694-y. Epub 2016 May 13.
3
[Multiple myeloma developing in a patient with immune thrombocytopenia].
Rinsho Ketsueki. 2016 May;57(5):630-3. doi: 10.11406/rinketsu.57.630.
4
[Idiopathic thrombocytopenic purpura in children].
Med Pregl. 1998 Mar-Apr;51(3-4):127-34.
5
Successful management of refractory immune thrombocytopenia associated with massive alveolar hemorrhage.
Transfus Apher Sci. 2015 Apr;52(2):214-6. doi: 10.1016/j.transci.2015.01.001. Epub 2015 Jan 8.
6
Complete remission of multiple myeloma after autoimmune hemolytic anemia: possible association with interferon-alpha.
Am J Hematol. 2007 Jun;82(6):489-92. doi: 10.1002/ajh.20875.
7
Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.
Int Immunopharmacol. 2012 Jul;13(3):242-4. doi: 10.1016/j.intimp.2012.04.015. Epub 2012 May 3.
8
Management of adult idiopathic thrombocytopenic purpura.
Annu Rev Med. 2005;56:425-42. doi: 10.1146/annurev.med.56.082103.104644.
9
Multiple myeloma and immune thrombocytopenia.
Clin Lab Haematol. 2000 Aug;22(4):239-42. doi: 10.1046/j.1365-2257.2000.00125.x.
10
Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
Eur J Haematol. 2011 Mar;86(3):256-9. doi: 10.1111/j.1600-0609.2010.01561.x. Epub 2011 Jan 11.
引用本文的文献
1
Can you Diagnose Immune Thrombocytopenia in Myeloma? A Case of Thrombocytopenia in a Patient with Multiple Myeloma.
Eur J Case Rep Intern Med. 2024 Nov 11;11(12):004981. doi: 10.12890/2024_004981. eCollection 2024.
2
Rituximab resistance in ITP and beyond.
Front Immunol. 2023 Jul 28;14:1215216. doi: 10.3389/fimmu.2023.1215216. eCollection 2023.
3
Multiple myeloma with concurrent immune thrombocytopenic purpura.
Ecancermedicalscience. 2020 Feb 20;14:1012. doi: 10.3332/ecancer.2020.1012. eCollection 2020.
本文引用的文献
1
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
Blood. 2015 Mar 5;125(10):1541-7. doi: 10.1182/blood-2014-06-581868. Epub 2015 Jan 9.
2
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44. doi: 10.3322/caac.21252. Epub 2014 Sep 29.
3
Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.
Int Immunopharmacol. 2012 Jul;13(3):242-4. doi: 10.1016/j.intimp.2012.04.015. Epub 2012 May 3.
4
The ITP syndrome: pathogenic and clinical diversity.
Blood. 2009 Jun 25;113(26):6511-21. doi: 10.1182/blood-2009-01-129155. Epub 2009 Apr 24.
5
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood. 2005 Dec 1;106(12):3777-84. doi: 10.1182/blood-2005-03-1173. Epub 2005 Aug 11.
6
AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Oncologist. 2005 Jun-Jul;10(6):412-26. doi: 10.1634/theoncologist.10-6-412.
7
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445.
8
Long-term outcomes in adults with chronic ITP after splenectomy failure.
Blood. 2004 Aug 15;104(4):956-60. doi: 10.1182/blood-2003-11-3908. Epub 2004 Apr 20.
9
Multiple myeloma and immune thrombocytopenia.
Clin Lab Haematol. 2000 Aug;22(4):239-42. doi: 10.1046/j.1365-2257.2000.00125.x.
10
Spectrum of AIDS-associated malignant disorders.
Lancet. 1998 Jun 20;351(9119):1833-9. doi: 10.1016/s0140-6736(97)09028-4.
Zotero 插件